GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortress Biotech Inc (NAS:FBIO) » Definitions » Cyclically Adjusted PB Ratio

Fortress Biotech (Fortress Biotech) Cyclically Adjusted PB Ratio : 0.11 (As of May. 13, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Fortress Biotech Cyclically Adjusted PB Ratio?

As of today (2024-05-13), Fortress Biotech's current share price is $1.70. Fortress Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $15.15. Fortress Biotech's Cyclically Adjusted PB Ratio for today is 0.11.

The historical rank and industry rank for Fortress Biotech's Cyclically Adjusted PB Ratio or its related term are showing as below:

FBIO' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.08   Med: 0.87   Max: 5.25
Current: 0.11

During the past years, Fortress Biotech's highest Cyclically Adjusted PB Ratio was 5.25. The lowest was 0.08. And the median was 0.87.

FBIO's Cyclically Adjusted PB Ratio is ranked better than
87.44% of 645 companies
in the Biotechnology industry
Industry Median: 1.79 vs FBIO: 0.11

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Fortress Biotech's adjusted book value per share data for the three months ended in Dec. 2023 was $1.493. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $15.15 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Fortress Biotech Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Fortress Biotech's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortress Biotech Cyclically Adjusted PB Ratio Chart

Fortress Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 3.12 2.11 0.55 0.20

Fortress Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.55 0.69 0.48 0.27 0.20

Competitive Comparison of Fortress Biotech's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Fortress Biotech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fortress Biotech's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortress Biotech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Fortress Biotech's Cyclically Adjusted PB Ratio falls into.



Fortress Biotech Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Fortress Biotech's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.70/15.15
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fortress Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Fortress Biotech's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.493/129.4194*129.4194
=1.493

Current CPI (Dec. 2023) = 129.4194.

Fortress Biotech Quarterly Data

Book Value per Share CPI Adj_Book
201403 25.589 99.695 33.219
201406 24.497 100.560 31.527
201409 23.445 100.428 30.213
201412 22.752 99.070 29.722
201503 19.272 99.621 25.037
201506 17.898 100.684 23.006
201509 17.061 100.392 21.994
201512 18.086 99.792 23.455
201603 13.778 100.470 17.748
201606 10.891 101.688 13.861
201609 11.241 101.861 14.282
201612 11.801 101.863 14.993
201703 14.233 102.862 17.908
201706 21.482 103.349 26.901
201709 10.955 104.136 13.615
201712 15.465 104.011 19.243
201803 11.858 105.290 14.576
201806 12.206 106.317 14.858
201809 10.084 106.507 12.253
201812 0.480 105.998 0.586
201903 4.946 107.251 5.968
201906 7.017 108.070 8.403
201909 5.501 108.329 6.572
201912 5.312 108.420 6.341
202003 7.107 108.902 8.446
202006 10.534 108.767 12.534
202009 15.538 109.815 18.312
202012 15.863 109.897 18.681
202103 16.332 111.754 18.914
202106 16.659 114.631 18.808
202109 14.079 115.734 15.744
202112 16.070 117.630 17.681
202203 13.806 121.301 14.730
202206 10.753 125.017 11.132
202209 8.544 125.227 8.830
202212 5.663 125.222 5.853
202303 4.347 127.348 4.418
202306 2.108 128.729 2.119
202309 1.865 129.860 1.859
202312 1.493 129.419 1.493

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Fortress Biotech  (NAS:FBIO) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Fortress Biotech Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Fortress Biotech's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Fortress Biotech (Fortress Biotech) Business Description

Traded in Other Exchanges
Address
1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.
Executives
Rosenwald Lindsay A Md director, 10 percent owner, officer: PRESIDENT, CEO & CHAIRMAN 375 PARK AVE, NEW YORK NY 10152
Lucy Lu director THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
David Jin officer: Chief Financial Officer C/O AVENUE THERAPEUTICS, INC., 1140 AVENUE OF THE AMERICAS, FLOOR 9, NEW YORK NY 10036
Dov Klein director C/O FORTRESS BIOTECH, INC., 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019
Robyn Hunter officer: Chief Financial Officer 95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453
Eric K Rowinsky director IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014
Malcolm Hoenlein director 750 LEXINGTON AVENUE, NEW YORK NY 10022
Michael S Weiss director, 10 percent owner, officer: EXECUTIVE VICE CHAIRMAN 750 LEXINGTON AVE, NEW YORK NY 10022
J Jay Lobell director 365 W END AVE, APARTMENT 10A, NEW YORK NY 10024
Jimmie Harvey director 3741 EAST FAIRWAY DRIVE, BIRMINGHAM AL 35213
Kevin Lorenz director C/O NUVEEN, 333 W. WACKER DR., CHICAGO IL 60606
George Avgerinos officer: SVP, Biologics Operations C/O CORONADO BIOSCIENCES, INC., 24 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Kevin Horgan other: Former Chief Medical Officer C/O SOLIGENIX, INC., 29 EMMONS DRIVE, STE. C-10, PRINCETON NJ 08540
David Jonathan Barrett director ONE PENN PLAZA, SUITE 2514, NEW YORK NY 10119
Harlan F Weisman director C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803

Fortress Biotech (Fortress Biotech) Headlines

From GuruFocus

Is Fortress Biotech Inc Undervalued Following the Latest Insider Buy?

By GuruFocus Research GuruFocus Editor 10-24-2022

Fortress Biotech Appoints David Jin as Chief Financial Officer

By PurpleRose PurpleRose 07-22-2022